<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Barbiturate (phenobarbital) poisoning</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Barbiturate (phenobarbital) poisoning</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Barbiturate (phenobarbital) poisoning</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ari Filip, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erica L Liebelt, MD, FACMT</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 19, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3857598335"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Barbiturates were first synthesized in 1903 as an alternative to existing sedative and hypnotic medications such as <a class="drug drug_general" data-topicid="9239" href="/z/d/drug information/9239.html" rel="external">chloral hydrate</a>, <a class="drug drug_general" data-topicid="83875" href="/z/d/drug information/83875.html" rel="external">paraldehyde</a>, and bromides [<a href="#rid1">1</a>]. They were increasingly used over the first half of the 20<sup>th</sup> century for treatment of psychiatric disease, seizures, insomnia, and induction of anesthesia, but patterns of misuse and dependence evolved concurrently [<a href="#rid2">2,3</a>]. Compared with benzodiazepines, barbiturates are more likely to cause respiratory depression in overdose. The evaluation and management of <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> poisoning has unique considerations compared with the other barbiturates.</p><p>This topic will discuss the evaluation and management of barbiturate poisoning, focusing on <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>. A rapid overview table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef143592" href="/z/d/graphic/143592.html" rel="external">table 1</a>). The following related content is discussed in separate topics:</p><p class="bulletIndent1"><span class="glyph">●</span>General discussion of the evaluation and management of the poisoned patient (see  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose"</a> and  <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">"Approach to the child with occult toxic exposure"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation of stupor and coma (see  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">"Evaluation of stupor and coma in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The pharmacology of antiseizure medications (see  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects"</a>)</p><p></p><p class="headingAnchor" id="H824625314"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Barbiturate poisoning has declined since the worldwide peak in the 1950 to 1960s, at one point accounting for over 3000 deaths per year in the United Kingdom [<a href="#rid4">4,5</a>]. This trend is likely due to the clinical use and popularization of benzodiazepines starting in 1960 coupled with the notoriety from high-profile overdose deaths, such as those of Marilyn Monroe and Jimi Hendrix. Approximately 1200 to 1400 single-substance barbiturate exposures are reported annually to United States poison control centers [<a href="#rid6">6-10</a>].</p><p>Barbiturates remain in clinical use with diverse indications, despite concerns over their safety profile. There has been renewed interest in <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> for treatment of alcohol withdrawal [<a href="#rid11">11-14</a>]. In Australia and some European countries, barbiturate-related deaths have increased, likely from use in self-harm attempts, despite an overall decline in poisoning cases and hospitalizations [<a href="#rid15">15-18</a>]. </p><p class="headingAnchor" id="H3738267897"><span class="h1">PHARMACOLOGY</span></p><p class="headingAnchor" id="H3887744600"><span class="h2">Mechanism of action</span><span class="headingEndMark"> — </span>Barbiturates enhance gamma-aminobutyric acid (GABA) receptor signaling, which is the primary inhibitory neurotransmitter in the central nervous system. Barbiturates increase the duration of GABA-A receptor subtype opening (an ionotropic chloride channel), thus increasing chloride influx and hyperpolarizing postsynaptic cell membranes [<a href="#rid19">19,20</a>]. At higher doses, barbiturates may act as direct agonists and open the receptor chloride channel, even in the absence of GABA [<a href="#rid21">21,22</a>]. Barbiturates also inhibit excitatory N-methyl-d-aspartate (NMDA) receptor signaling by indirect mechanisms [<a href="#rid23">23,24</a>].</p><p class="headingAnchor" id="H2437318095"><span class="h2">Commonly available agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenobarbital</strong> – <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> is a long-acting agent used to treat status epilepticus and seizure disorders. It is used as a sedative agent, such as to treat alcohol withdrawal syndrome and occasionally for mechanically ventilated patients [<a href="#rid25">25-27</a>]. Phenobarbital is a potent cytochrome P450 (CYP) inducer. (See  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Phenobarbital'</a> and  <a class="medical medical_review" href="/z/d/html/6201.html" rel="external">"Treatment of neonatal seizures", section on 'Antiseizure medication therapy'</a> and  <a class="medical medical_review" href="/z/d/html/323.html" rel="external">"Management of moderate and severe alcohol withdrawal syndromes", section on 'Refractory delirium tremens, including use of phenobarbital'</a> and  <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Barbiturates'</a>.) </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> doses &gt;40 mg/kg are considered potentially toxic (typical loading is 15 to 20 mg/kg), but sedation can occur even with therapeutic dosing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Butalbital</strong> – Butalbital is found primarily in combination products used for headache treatment alongside <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, caffeine, and/or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. (See  <a class="medical medical_review" href="/z/d/html/3347.html" rel="external">"Acute treatment of migraine in adults", section on 'Opioids and barbiturates'</a> and  <a class="medical medical_review" href="/z/d/html/3358.html" rel="external">"Tension-type headache in adults: Acute treatment", section on 'Limited role of combination analgesics containing barbiturates or opioids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primidone</strong> – Even though <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a> is classified as a barbiturate, its effect on the GABA receptor is primarily from metabolism to <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> [<a href="#rid28">28</a>]. Primidone is used to treat essential tremor and several seizure disorders [<a href="#rid29">29</a>]. Primidone can cause dose-related sedation and an acute neurotoxic reaction that includes dizziness, ataxia, nausea, and vomiting, likely unrelated to the phenobarbital metabolite [<a href="#rid28">28</a>]. Primidone does not appear to prolong the QT interval [<a href="#rid30">30,31</a>]. (See  <a class="medical medical_review" href="/z/d/html/4898.html" rel="external">"Essential tremor: Treatment and prognosis", section on 'Primidone'</a> and  <a class="medical medical_review" href="/z/d/html/2221.html" rel="external">"Antiseizure medications: Mechanism of action, pharmacology, and adverse effects", section on 'Primidone'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methohexital</strong> – <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">Methohexital</a> is an ultrashort-acting agent used for procedural sedation and induction of anesthesia, particularly for electroconvulsive therapy [<a href="#rid32">32</a>]. It may have some intrinsic proconvulsant effects [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">"General anesthesia: Intravenous induction agents", section on 'Methohexital'</a> and  <a class="medical medical_review" href="/z/d/html/139217.html" rel="external">"Procedural sedation in adults in the emergency department: Medication selection, dosing, and discharge criteria", section on 'Barbiturates'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thiopental</strong> – Thiopental is an ultrashort-acting agent used for induction of anesthesia, especially in patients with conditions that can elevate intracranial pressure (ICP) and seizure control in refractory status epilepticus. It is a venodilator with negative cardiac inotropic effects and can induce profound hypotension. (See  <a class="medical medical_review" href="/z/d/html/271.html" rel="external">"Induction agents for rapid sequence intubation in adults for emergency medicine and critical care", section on 'Barbiturates'</a> and  <a class="medical medical_review" href="/z/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Infusion therapies and other treatments'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pentobarbital</strong> – <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">Pentobarbital</a> is used as an adjunct for refractory status epilepticus and to induce coma in patients requiring aggressive control of elevated ICP [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/132561.html" rel="external">"Refractory status epilepticus in adults", section on 'Pentobarbital'</a> and  <a class="medical medical_review" href="/z/d/html/1659.html" rel="external">"Evaluation and management of elevated intracranial pressure in adults", section on 'Barbiturates'</a>.)</p><p></p><p class="headingAnchor" id="H227659376"><span class="h2">Pharmacokinetics</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Absorption</strong> – Barbiturates and barbiturate salts generally have good oral bioavailability and are primarily absorbed in the small intestine. <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> has &gt;95 percent oral bioavailability with a time-to-peak concentration of 0.5 to 4 hours [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution</strong> – Barbiturates generally have a low volume of distribution  (<a class="graphic graphic_table graphicRef143593" href="/z/d/graphic/143593.html" rel="external">table 2</a>). The long-acting barbiturates such as <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> have lower volumes of distribution (0.6 to 1.0 L/kg) compared with the short-acting barbiturates, such as thiopental (4.4 L/kg) [<a href="#rid38">38-40</a>]. Barbiturates are weak acids, with pKa generally ranging from 7.3 (phenobarbital) to 8.1 (<a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">pentobarbital</a>). There is varied serum protein binding; phenobarbital is 48 percent protein bound, but these binding sites are saturated in overdose, resulting in a greater free fraction [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Metabolism</strong> – Barbiturates are primarily metabolized via the hepatic CYP system and n-glucuronidation [<a href="#rid42">42</a>]. They also undergo extensive enterohepatic recirculation; biliary concentrations can be tenfold greater than those in the plasma [<a href="#rid43">43</a>]. Chronic <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> use can enhance its own elimination and that of many other agents because it is a potent inducer of several CYP isoenzymes and uridine diphosphate-glucuronosyltransferase-glucuronidation [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elimination</strong> – Barbiturate elimination half-life only partially correlates with duration of action, which is largely determined by rate of distribution out of the central nervous system. Highly lipid soluble and highly protein-bound barbiturates, such as thiopental and <a class="drug drug_general" data-topicid="9629" href="/z/d/drug information/9629.html" rel="external">methohexital</a>, redistribute quickly and have a duration of effect of only several minutes despite long terminal elimination half-lives (eg, 9 to 11 hours for thiopental) [<a href="#rid46">46</a>]. Less lipid soluble drugs with lower protein binding, such as <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, have longer durations of effect (eg, 10 to 12 hours), with an elimination half-life of 70 to 140 hours [<a href="#rid42">42,47</a>]. Elimination is renal following hepatic metabolism. A minor fraction of many barbiturates (generally &lt;30 percent; 25 percent for phenobarbital) are excreted unchanged in the urine. Phenobarbital elimination can be enhanced by urinary alkalinization since it is a weak acid and by multidose activated charcoal since it undergoes enterohepatic recirculation [<a href="#rid48">48-50</a>]. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons"</a>.)</p><p></p><p class="headingAnchor" id="H3102367252"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H722332347"><span class="h2">Sedation/coma</span><span class="headingEndMark"> — </span>Barbiturates produce dose-dependent sedation ranging from decreased alertness and ataxia to coma and suppression of brainstem reflexes [<a href="#rid51">51</a>]. They can cause a neurologic examination that mimics brain death  (<a class="graphic graphic_table graphicRef142111" href="/z/d/graphic/142111.html" rel="external">table 3</a>) and may even perturb cerebral flow studies [<a href="#rid52">52,53</a>]. The duration of their sedative effects following intentional overdose may be vastly prolonged compared with therapeutic use; for example, a patient was comatose with suppressed brainstem reflexes for five days following an intentional <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">pentobarbital</a> ingestion [<a href="#rid54">54</a>].</p><p>However, the degree of sedation often does not correlate with the serum drug concentration, which is discussed further below. (See <a class="local">'Specific serum drug concentrations'</a> below.) </p><p class="headingAnchor" id="H2606683660"><span class="h2">Respiratory depression</span><span class="headingEndMark"> — </span>Barbiturates are potent central respiratory depressants, initially characterized by decreased tidal volume that can proceed to apnea with sufficient doses [<a href="#rid55">55-58</a>]. This dose-dependent respiratory depression contributes to the relatively narrow therapeutic index of barbiturates compared with benzodiazepines [<a href="#rid59">59</a>]. Respiratory depression is synergistic when barbiturates are combined with other sedatives and/or opioids [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H1107157253"><span class="h2">Cardiovascular depression</span><span class="headingEndMark"> — </span>Barbiturates can cause hypotension following overdose, likely due to insensible fluid losses, increased venous capacitance, and preload dependence with an associated reduction in cardiac output [<a href="#rid61">61-64</a>]. The peripheral vascular resistance is often normal or increased. Some agents such as thiopental may cause more profound cardiovascular depression [<a href="#rid65">65-69</a>]. Barbiturates do not appear to be intrinsically arrhythmogenic, but bradycardia and compensatory tachycardia have been reported [<a href="#rid62">62-64</a>]. Barbiturate poisoning may induce a hypometabolic state characterized by decreased myocardial and systemic oxygen demand [<a href="#rid70">70-72</a>].</p><p class="headingAnchor" id="H715553959"><span class="h2">Hypothermia</span><span class="headingEndMark"> — </span>Thermoregulatory dysfunction, specifically hypothermia, is common following barbiturate poisoning [<a href="#rid73">73-76</a>]. Temperatures as low as 21ºC (70ºF) have been reported with severe poisoning [<a href="#rid73">73</a>]. Rebound hyperthermia also commonly occurs, likely from physiologic heat conservation [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H1672295634"><span class="h2">Skin bullae (barb blisters)</span><span class="headingEndMark"> — </span>Barbiturate poisoning can cause drug-induced bullae, often called "coma blisters" or "barb blisters," which are characteristically tense, subepidermal, sterile bullae typically occurring 24 to 72 hours following intoxication [<a href="#rid78">78-80</a>]. These are self-limited, resolving in weeks [<a href="#rid81">81</a>]. Bullae formation is likely from pressure and hypoxia since they often occur at dependent sites, but they have also been reported in noncomatose patients  (<a class="graphic graphic_picture graphicRef142931" href="/z/d/graphic/142931.html" rel="external">picture 1</a>) and at nondependent sites [<a href="#rid82">82-85</a>]. Although coma blisters can occur following poisoning with other sedatives [<a href="#rid86">86-89</a>], they are most closely associated with barbiturates [<a href="#rid80">80,90</a>]. (See  <a class="medical medical_review" href="/z/d/html/13684.html" rel="external">"Approach to the patient with cutaneous blisters", section on 'Localized distribution'</a>.)</p><p class="headingAnchor" id="H2030916476"><span class="h2">Others</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiosyncratic drug reactions</strong> – Although typically occurring with therapeutic use and not poisoning, barbiturates are a rare cause (6 percent) of drug reaction with eosinophilia and systemic symptoms (DRESS), similar to other aromatic antiseizure medications [<a href="#rid91">91-94</a>]. <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a> has been implicated in up to 10 percent of cases of Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN), accounting for half of cases caused by antiseizure medications [<a href="#rid95">95</a>]. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a> and  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a>, unlike other barbiturates, has been implicated in cases of drug-induced liver injury, usually in conjunction with other manifestations of drug hypersensitivity (eg, DRESS, SJS, TEN) [<a href="#rid96">96</a>]. Aminotransferase elevation is typically mild and resolves with drug discontinuation. (See  <a class="medical medical_review" href="/z/d/html/3571.html" rel="external">"Drug-induced liver injury"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous formulation diluent</strong> <strong>toxicity</strong> – Intravenous administration of high doses of barbiturates that may contain propylene glycol (eg, <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">pentobarbital</a>, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>) predisposes patients to propylene glycol toxicity [<a href="#rid1">1,97-99</a>]. Manifestations include hypotension, bradycardia, depressed mental status, and a metabolic acidosis with hyperlactemia and increased serum osmolality. Substitution with an intravenous benzodiazepine may not obviate this problem since some formulations (eg, <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">lorazepam</a>, <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">diazepam</a>) may also contain propylene glycol. (See  <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">"Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Propylene glycol toxicity'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypokalemia</strong> – Hypokalemia commonly occurs with therapeutic use of thiopental, which may be profound (eg, serum potassium concentration &lt;2.0 mEq/L) in one-quarter of patients [<a href="#rid100">100-105</a>]. Hypokalemia can also occur less frequently with <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">pentobarbital</a> [<a href="#rid106">106,107</a>]. The mechanism is likely multifactorial, potentially involving neuronal potassium currents, metabolic interactions, and catecholamine-mediated pathways [<a href="#rid105">105,108</a>]. Rebound hyperkalemia is common and can be life threatening [<a href="#rid102">102,105</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crystalluria</strong> – <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">Primidone</a> overdose has been reported to cause crystalluria [<a href="#rid109">109</a>]. </p><p></p><p class="headingAnchor" id="H840889273"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Barbiturate poisoning produces a sedative-hypnotic toxidrome, which is characterized by depressed mental status and either mostly normal vital signs or a varying degree of respiratory and/or cardiovascular depression depending on the agent  (<a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">table 4</a>). In any suspected ingestion when the patient cannot provide a history, an exploration of alternative sources of information is warranted, including but not exclusive to emergency medical services, family members, pill bottles if available, medical records, and pharmacy information. Other common ingestions that present similarly to barbiturate poisoning include:</p><p class="bulletIndent1"><span class="glyph">●</span>Ethanol intoxication, which can be assessed by obtaining serum concentrations or using an alcohol breathalyzer. (See  <a class="medical medical_review" href="/z/d/html/333.html" rel="external">"Ethanol intoxication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6487.html" rel="external">"Ethanol intoxication in children: Clinical features, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opioid intoxication causes depressed mental status, decreased respiratory rate, and miotic pupils that improve after <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> administration. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benzodiazepine, <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">zolpidem</a>, <a class="drug drug_general" data-topicid="10126" href="/z/d/drug information/10126.html" rel="external">zopiclone</a>, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, and <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">trazodone</a> are examples of commonly misused sedatives that can only be excluded by history. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning"</a> and  <a class="medical medical_review" href="/z/d/html/139762.html" rel="external">"Gabapentinoid poisoning and withdrawal"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gamma hydroxybutyrate (GHB) intoxication, which often manifests as coma followed by abrupt awakening. GHB intoxication is difficult to distinguish from other causes of obtundation without a clear history. <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">Baclofen</a>, also a gamma-aminobutyric acid (GABA)-B agonist, can cause profound sedation with more indolent and prolonged time course. (See  <a class="medical medical_review" href="/z/d/html/307.html" rel="external">"Gamma hydroxybutyrate (GHB) intoxication"</a> and  <a class="medical medical_review" href="/z/d/html/141081.html" rel="external">"GABA-B agonist (baclofen, phenibut) poisoning and withdrawal"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atypical antipsychotic agents (eg, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>), which are commonly misused and intentionally ingested, can cause sedation as well as tachycardia and anticholinergic delirium. (See  <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">"Second-generation antipsychotic medications: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/z/d/html/305.html" rel="external">"Anticholinergic poisoning"</a>.) </p><p></p><p>Sedation and coma  (<a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">table 5</a>) are found in a wide range of medical and toxicologic conditions (see  <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">"Stupor and coma in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">"Evaluation of stupor and coma in children"</a>). Unless the diagnosis of barbiturate poisoning is obvious, other life-threatening nontoxicologic causes must be considered in the differential diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypoglycemia must be excluded in every patient with altered mental status, even if barbiturate poisoning is suspected.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with an intentional ingestion, the presence of coingestants should be investigated. (See  <a class="medical medical_review" href="/z/d/html/324.html" rel="external">"General approach to drug poisoning in adults", section on 'Diagnosis of poisoning'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Altered mental status in association with fever or leukocytosis raises concern for meningitis or other infections and warrants a thorough evaluation, often including assessment of the cerebral spinal fluid. (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">"Viral encephalitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6043.html" rel="external">"Acute viral encephalitis in children: Pathogenesis, epidemiology, and etiology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any focal neurologic findings or seizures raise concern for a central nervous system process such as stroke, intracranial hemorrhage, or encephalitis. (See  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke"</a> and  <a class="medical medical_review" href="/z/d/html/2219.html" rel="external">"Evaluation and management of the first seizure in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of trauma or clinical findings of injuries should prompt obtaining a head computed tomography (CT) scan. (See  <a class="medical medical_review" href="/z/d/html/13854.html" rel="external">"Initial management of trauma in adults"</a>.)</p><p></p><p class="headingAnchor" id="H3999514778"><span class="h1">EVALUATION AND DIAGNOSTIC TESTING</span></p><p class="headingAnchor" id="H3832697473"><span class="h2">History and examination</span><span class="headingEndMark"> — </span>A patient with barbiturate poisoning may have sedation and be unable to provide a history, which may need to be obtained from family, caregivers, emergency medical personnel, or bystanders. In a patient with suspected poisoning, try to ascertain the reason to suspect an overdose (eg, suicide note, witnessed), time of ingestion, intent (eg, self-harm versus misuse), potential coingestants, other accessible medications, last time patient was seen without signs of toxicity, prior medical history, and prior history of self-harm attempts. If the ingested agent is unclear, checking electronic medical records or drug monitoring databases, where available, may reveal an active barbiturate prescription. A history of a condition that is treated with barbiturates (eg, seizure disorder, alcohol use disorder, essential tremor, migraine headache) in the patient or a family member may also provide a clue to poisoning with a barbiturate. </p><p>We perform a targeted physical examination assessing vital signs, mental status, ability to protect airway, respirations, focal neurologic deficits, evidence of self-injury, and presence of specific toxidromes  (<a class="graphic graphic_table graphicRef71268" href="/z/d/graphic/71268.html" rel="external">table 4</a>). Ensure that a core temperature is measured. A patient with an unknown downtime should be evaluated for signs of compartment syndrome or traumatic myositis (eg, palpation of muscle compartments, including paraspinal and gluteal muscles). Examine the skin for bullae, which may provide a clue of barbiturate poisoning if the diagnosis is in doubt. (See <a class="local">'Skin bullae (barb blisters)'</a> above.)</p><p class="headingAnchor" id="H2448890647"><span class="h2">Routine laboratory studies and electrocardiogram</span><span class="headingEndMark"> — </span>In a patient with somnolence, including when a barbiturate ingestion is suspected, we obtain the following, aimed at excluding other diagnoses:</p><p class="bulletIndent1"><span class="glyph">●</span>Fingerstick blood glucose to rule out hypoglycemia as the cause of altered mental status</p><p class="bulletIndent1"><span class="glyph">●</span>Serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, salicylate, and ethanol concentrations to rule out these common coingestants</p><p class="bulletIndent1"><span class="glyph">●</span>An electrocardiogram to evaluate for drug-induced cardiotoxic effects (more likely to occur from a coingestant)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum chemistries, creatinine, and creatine kinase to assess for metabolic derangements, kidney function, and exclude rhabdomyolysis</p><p class="bulletIndent1"><span class="glyph">●</span>Pregnancy test in females of childbearing age</p><p></p><p class="headingAnchor" id="H1572072745"><span class="h2">Specific serum drug concentrations</span></p><p class="headingAnchor" id="H2760784495"><span class="h3">Phenobarbital</span><span class="headingEndMark"> — </span>In a patient with a history of <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> ingestion or a patient with depressed mental status and potential phenobarbital exposure, we obtain a serum phenobarbital concentration. Most clinical hospital laboratories can provide a quantitative result within two hours [<a href="#rid110">110</a>]. The therapeutic range is 10 to 40 mcg/mL (43 to 172 micromole/L). Concentrations &gt;80 mcg/mL (344 micromole/L) are considered potentially fatal and &gt;100 mcg/mL (430 micromole/L) are typically fatal without intervention [<a href="#rid64">64,111,112</a>].</p><p>In a patient with <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> poisoning or a supratherapeutic concentration, we obtain serial concentrations (eg, every 8 to 12 hours) to monitor trajectory. Serum concentrations often do not correlate with the degree of coma and cardiorespiratory collapse [<a href="#rid113">113</a>]. Possible reasons include presence of coingestants, development of tolerance to the barbiturate, and discordance between serum and central nervous system (the active compartment) concentrations. An increasing concentration may reflect redistribution (and thus correlate with earlier clinical effects) or continued absorption.</p><p class="headingAnchor" id="H2637907126"><span class="h3">Other barbiturates</span><span class="headingEndMark"> — </span>Quantitative testing for other barbiturates is not useful in the acute management of the somnolent patient since these assays are not readily available at most clinical laboratories and have long turnaround times. Testing performed at a reference laboratory might still be helpful if confirmatory forensic testing is needed (eg, child with altered mental status in whom poisoning is suspected), a brain death declaration is considered in a patient with suspected barbiturate overdose, or to exclude barbiturate poisoning as a cause of prolonged coma [<a href="#rid114">114</a>]. Serum concentrations of short-acting barbiturates &gt;35 mcg/mL (150 micromole/L) are associated with potentially fatal ingestions [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H2864930419"><span class="h2">Role of urine drug immunoassays</span><span class="headingEndMark"> — </span>Urine "drug of abuse" (DOA) testing can often be misleading and typically has a very limited role in the acute management of the poisoned patient  (<a class="graphic graphic_table graphicRef95110" href="/z/d/graphic/95110.html" rel="external">table 6</a>). These immunoassays are a test of use and not intoxication, have many false-positive and false-negative results, and thus can lead to premature diagnostic closure. Even though clinically available urine drug immunoassays will reveal the presence of most barbiturates with good sensitivity and specificity, these qualitative tests do not confirm barbiturate poisoning as the sole cause of the patient's signs and symptoms [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">"Testing for drugs of abuse (DOAs)"</a>.)</p><p>In young children, some experts will obtain a urine DOA screen since a positive result is suggestive of poisoning [<a href="#rid116">116</a>]. However, a positive result can also occur from prescribed barbiturates or from a cross-reaction with <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a>, <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">naproxen</a>, or <a class="drug drug_general" data-topicid="9440" href="/z/d/drug information/9440.html" rel="external">ethosuximide</a>, and thus should be confirmed with advanced laboratory methods (eg, gas chromatography with mass spectrophotometry) [<a href="#rid117">117-119</a>]. (See  <a class="medical medical_review" href="/z/d/html/130622.html" rel="external">"The substance-exposed child: Clinical features and diagnosis", section on 'Toxicology testing'</a>.)</p><p class="headingAnchor" id="H2131585640"><span class="h2">Role of imaging and other studies</span><span class="headingEndMark"> — </span>We obtain other studies based on clinical indication. As examples, CT scan of the head is indicated in a patient with altered mental status if there is a history of trauma or if the history of drug intoxication is uncertain. A chest radiograph should be obtained if there is concern for aspiration (eg, hypoxia). </p><p class="headingAnchor" id="H543258400"><span class="h1">DIAGNOSIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenobarbital</strong> – The diagnosis of <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> poisoning is suspected in a patient with a depressed mental status and a history of exposure to phenobarbital. The diagnosis of phenobarbital poisoning is confirmed in a patient with depressed mental status and a supratherapeutic serum phenobarbital concentration (&gt;40 mcg/mL [172 micromole/L]). However, the concentration does not reliably predict the severity or duration of toxicity [<a href="#rid120">120</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other barbiturates</strong> – Barbiturate poisoning (other than <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>) is a clinical diagnosis and usually suspected in a patient with depressed mental status and corroborating history (eg, access to barbiturates) or a urine drug screen (if obtained) that detects a barbiturate. In the absence of clear corroborating history, barbiturate poisoning should still be considered a diagnosis of exclusion since confirmatory serum concentrations are not readily available. Nontoxicologic and other toxicologic etiologies must be ruled out, especially conditions in which diagnostic delay will hold up critical interventions and definitive care. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H2910340152"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H2234110031"><span class="h2">All patients/barbiturates: supportive care</span><span class="headingEndMark"> — </span>As with any potentially critically ill patient, initial management begins with rapidly assessing and addressing the patient's airway, breathing, and circulation. In a patient who presents with anything more than trivial sedation, we suggest establishing intravenous access and continuous cardiac monitoring. End tidal carbon dioxide (E<sub>t</sub>CO<sub>2</sub>; ie, capnography) is useful for monitoring patients at risk for hypoventilation. Supplemental oxygen should be administered as needed. Placing a nasopharyngeal airway (ie, nasal trumpet) may help overcome upper airway obstruction from central nervous system depression in a patient who is breathing spontaneously. (See  <a class="medical medical_review" href="/z/d/html/267.html" rel="external">"Basic airway management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6383.html" rel="external">"Basic airway management in children"</a> and  <a class="medical medical_review" href="/z/d/html/273.html" rel="external">"Carbon dioxide monitoring (capnography)"</a>.)</p><p>We suggest not administering <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> to a patient with suspected barbiturate poisoning. Flumazenil is a nonspecific competitive antagonist of the benzodiazepine receptor on the gamma-aminobutyric acid (GABA) channel. It would not be expected to improve barbiturate intoxication and may precipitate benzodiazepine withdrawal if the patient has a benzodiazepine coingestion. Its use in the somnolent patient with benzodiazepine poisoning is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/314.html" rel="external">"Benzodiazepine poisoning", section on 'Role of antidote (flumazenil)'</a>.)</p><p class="headingAnchor" id="H1145161951"><span class="h3">Respiratory depression</span><span class="headingEndMark"> — </span>In a somnolent patient with suspected barbiturate poisoning who has a low respiratory rate, we suggest a trial of parenteral or intranasal <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> given the possibility of opioid coingestion. Naloxone would not be expected to reverse the effects of the barbiturate itself but may improve mental status or respiration if the patient is also suffering opioid intoxication. (See  <a class="medical medical_review" href="/z/d/html/300.html" rel="external">"Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'</a> and  <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents", section on 'Naloxone'</a>.)</p><p>Tracheal intubation and mechanical ventilation will most likely be required in a patient with respiratory depression from barbiturate poisoning, especially if there is no improvement following <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a> (if administered). (See  <a class="medical medical_review" href="/z/d/html/277.html" rel="external">"Mechanical ventilation of adults in the emergency department"</a> and  <a class="medical medical_review" href="/z/d/html/109649.html" rel="external">"Initiating mechanical ventilation in children"</a>.)</p><p class="headingAnchor" id="H2454357617"><span class="h3">Hypotension</span><span class="headingEndMark"> — </span>Hypotension is treated with a rapid infusion of isotonic crystalloid, followed by vasopressors (eg, norepinephrine, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>) if needed. Increase in plasma volume has been associated with increased cardiac output and improved blood pressure [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/z/d/html/13850.html" rel="external">"Initial management of the critically ill adult with an unknown overdose", section on 'Hypotension'</a> and  <a class="medical medical_review" href="/z/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>.)</p><p class="headingAnchor" id="H2891070411"><span class="h2">Modalities with limited roles</span></p><p class="headingAnchor" id="H3377028933"><span class="h3">Gastrointestinal decontamination</span><span class="headingEndMark"> — </span>We suggest not performing routine gastrointestinal decontamination with activated charcoal (AC) in a patient with an isolated barbiturate ingestion (except for <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, discussed below) since intoxication will often improve with supportive care and metabolism of the barbiturate. Administering single-dose AC may not provide additional benefits but can increase the risk of aspiration and complicate airway management if the patient loses airway protective reflexes. (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Activated charcoal'</a>.)</p><p class="headingAnchor" id="H4285588185"><span class="h3">Enhanced elimination</span><span class="headingEndMark"> — </span>Urinary alkalinization may increase elimination of any long-acting barbiturate (eg, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, barbital, <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>) since they are weak acids and less lipophilic (compared with short- and medium-acting barbiturates) [<a href="#rid50">50</a>]. However, there is insufficient evidence to routinely recommend this modality for a patient poisoned by barbiturates other than phenobarbital. For a patient with long-acting barbiturate poisoning and hemodynamic instability or deep sedation (eg, does not awaken with verbal stimuli), we recommend consultation with a poison center or medical toxicologist to discuss modalities to increase elimination. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Urinary alkalinization'</a> and <a class="local">'Regional poison centers'</a> below.)</p><p>There is insufficient evidence to routinely recommend multidose activated charcoal (MDAC) or hemodialysis for a patient poisoned by barbiturates other than <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>. The use of these modalities for phenobarbital poisoning is discussed immediately below. </p><p class="headingAnchor" id="H167367653"><span class="h2">Patient with phenobarbital poisoning and moderate to severe toxicity</span><span class="headingEndMark"> — </span>In a patient with <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> poisoning and moderate to severe toxicity, we suggest MDAC and urinary alkalinization in addition to supportive care. We consider moderate toxicity as depressed mental status that does not improve with verbal stimuli and a phenobarbital concentration &gt;40 mcg/mL (172 micromole/L) and severe toxicity as hypotension requiring the use of vasopressors or cardiovascular collapse. Severe toxicity typically occurs with concentrations &gt;80 mcg/mL (344 micromole/L) but may occur with lower concentrations [<a href="#rid120">120</a>]. </p><p>In a patient with <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> poisoning and severe toxicity or prolonged coma and/or increasing serum phenobarbital concentrations despite MDAC and urinary alkalinization, we recommend hemodialysis in addition to MDAC, urinary alkalinization, and supportive care. (See <a class="local">'Hemodialysis'</a> below.)</p><p class="headingAnchor" id="H3106290487"><span class="h3">Multidose activate charcoal (MDAC)</span><span class="headingEndMark"> — </span>MDAC increases <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> clearance but should only be performed in a patient with a protected airway (ie, tracheally intubated). However, tracheal intubation should not be performed for the sole purpose of providing MDAC. We also do not perform MDAC if there are signs of bowel obstruction or ileus (eg, lack of bowel sounds). (See  <a class="medical medical_review" href="/z/d/html/321.html" rel="external">"Gastrointestinal decontamination of the poisoned patient", section on 'Multidose activated charcoal'</a>.)</p><p>We place a nasogastric or orogastric tube to facilitate administration of AC. The initial dose is 50 g (adults) or 1 g/kg (pediatric) with or without cathartic. Subsequent doses are 12.5 g (or 0.25 g/kg) per hour, which can be administered continuously or in divided doses every two, four, or six hours (eg, 50 g every four hours) <strong>without</strong> a cathartic. Serial <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> concentrations (eg, every 8 to 12 hours) should be obtained to guide duration of MDAC. We continue MDAC until the patient is clinically improving and the phenobarbital serum concentration is less than 40 mcg/mL (172 micromole/L). </p><p>A trial of 20 comatose, mechanically ventilated patients with <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> poisoning found that MDAC reduced the elimination half-life of phenobarbital (36 versus 93 hours) but did not significantly reduce the time of mechanical ventilation (39 versus 48 hours) [<a href="#rid121">121</a>]. A study of 30 patients (15 with mechanical ventilation) with phenobarbital poisoning found that, compared with urinary alkalinization alone, treatment with MDAC alone or MDAC with urinary alkalinization was associated with a decreased time of mechanical ventilation (40 and 52 versus 79 hours) and shorter phenobarbital plasma half-life (39 and 51 versus 81 hours) [<a href="#rid48">48</a>]. A study of six patients with moderate to severe phenobarbital poisoning treated with MDAC found that the elimination half-life was 12 hours immediately following MDAC (the typical half-life is 70 to 140 hours), and all patients had faster recovery in mental status than expected [<a href="#rid122">122</a>]. Animal and volunteer evidence has found that MDAC increases clearance of intravenous phenobarbital, suggesting the mechanism is more than just limiting gastrointestinal absorption [<a href="#rid123">123,124</a>]. A study of volunteers who received therapeutic doses of phenobarbital found that MDAC reduced the half-life up to 59 and 82 percent for intravenous and oral administration, respectively [<a href="#rid124">124</a>]. </p><p>A workgroup composed of members from the American Academy of Clinical Toxicology (AACT) and European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) estimated a <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> clearance of 84 mL/min with MDAC, compared with 49, 7, and 4 mL/min for hemodialysis, urine alkalinization, and endogenous, respectively [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H821320863"><span class="h3">Urinary alkalinization</span><span class="headingEndMark"> — </span>Urinary alkalinization increases <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> clearance but to a lesser extent compared with MDAC [<a href="#rid50">50</a>]. We alkalinize urine in combination with MDAC or alone when MDAC is contraindicated or cannot be performed. The urine is alkalinized by administering an intravenous bolus of 1 to 2 mEq/kg of an 8.4 percent solution of <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> followed by an infusion of 150 mEq/L solution of sodium bicarbonate at 200 to 250 mL/hour (adults) or 1.5 times maintenance (children). The administration, monitoring, and urine pH goal are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Technique'</a>.)</p><p>We continue urinary alkalinization until the patient is clinically improving and the <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> serum concentration is less than 40 mcg/mL (172 micromole/L). Potassium supplementation may be required during a <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">sodium bicarbonate</a> infusion. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Complications'</a>.)</p><p>Alkalinizing the urine leads to a marked excretion of weak acids such as <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>; the mechanism is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'General concepts and mechanism'</a> and  <a class="medical medical_review" href="/z/d/html/140354.html" rel="external">"Salicylate (aspirin) poisoning: Management", section on 'Serum and urine alkalinization'</a>.)</p><p>In a study of volunteers who received a therapeutic intravenous <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> dose, urinary alkalinization decreased the elimination half-life compared with control (47 versus 148 hours) but to a lesser extent compared with MDAC (19 hours) [<a href="#rid49">49</a>]. Several small studies have found that urine alkalinization is associated with increased phenobarbital clearance [<a href="#rid126">126-128</a>]. </p><p class="headingAnchor" id="H1890220285"><span class="h3">Hemodialysis</span><span class="headingEndMark"> — </span>Extracorporeal removal (ie, hemodialysis) should be reserved for a phenobarbital-poisoned patient with hemodynamic instability or prolonged coma not improving with MDAC and urinary alkalinization. Intermittent hemodialysis is the preferred technique, but continuous renal replacement therapy is an alternative in cases where intermittent hemodialysis might not be tolerated [<a href="#rid129">129-132</a>]. (See  <a class="medical medical_review" href="/z/d/html/325.html" rel="external">"Enhanced elimination of poisons", section on 'Extracorporeal removal'</a>.)</p><p>The evidence for hemodialysis in <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> poisoning is based on case reports, case series, and measured hemodialysis clearance [<a href="#rid111">111,132-134</a>]. For example, in a case report, the phenobarbital clearance was an average of 174 mL/min during hemodialysis with a high-flux, high-efficiency membrane and blood flow rate of 400 mL/min [<a href="#rid120">120</a>]. This is significantly greater than prior reported hemodialysis or hemoperfusion clearance rates (approximately 50 to 90 mL/min), likely due to the high-efficiency dialyzer technique. A study of 25 patients with coma following phenobarbital overdose found that, compared with forced alkaline diuresis, hemodialysis was associated with a higher mean reduction in serum concentrations (63 versus 40 percent) and a shorter duration of coma (12 versus 61 hours) [<a href="#rid134">134</a>]. </p><p>However, studies or trials comparing the effectiveness of hemodialysis with MDAC do not exist. Since MDAC is generally safe (in a patient with a protected airway) and effectively increases clearance of <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, we suggest MDAC and urinary alkalinization as first-line therapy in a hemodynamically stable patient. When MDAC specifically is contraindicated (eg, ileus) or has failed (eg, has not improved mental status or decreased serum concentrations), hemodialysis is a reasonable alternative to increase clearance. If prolonged coma is expected, shortening the duration of coma outweighs potential complications of hemodialysis since prolonged mechanical ventilation has potential complications (eg, ventilator-associated pneumonia). Additionally, toxicity affecting autonomic control of circulatory function and causing hemodynamic instability (eg, hypotension requiring vasopressor, malignant dysrhythmias) suggests a high mortality, thus warranting aggressive measures to increase elimination. Our recommendations are consistent with those from the Extracorporeal Treatments In Poisoning (EXTRIP) workgroup, who similarly prefer hemodialysis for cases of severe or prolonged long-acting barbiturate poisoning or cases where MDAC and supportive therapy have failed [<a href="#rid111">111</a>].</p><p class="headingAnchor" id="H2839335980"><span class="h1">DISPOSITION</span><span class="headingEndMark"> — </span>A patient with significant respiratory depression, an inability for airway protection, hypotension, or exposure to a dangerous coingestant should be admitted to a critical care setting.</p><p>Most patients with an isolated barbiturate ingestion can be safely discharged or cleared for psychiatric evaluation following an observation period of six hours, provided that any concerning symptoms, such as central nervous system depression, have resolved. The patient should be able to ambulate safely prior to discharge. If the patient has an opioid coingestion or opioid use disorder, they should be counseled about the risk of respiratory depression from barbiturate coingestion and offered referral to substance use disorder treatment. A patient with persistent signs of intoxication beyond six hours should be admitted to a monitored setting until symptoms resolve. A patient with a coingestion of an opioid, anticholinergic agent, or medication that may form a bezoar (eg, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) should be closely monitored until the peak clinical effect has been reached, as drug absorption can be delayed.</p><p class="headingAnchor" id="H1629431678"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H4117296492"><span class="h2">Pediatrics</span><span class="headingEndMark"> — </span>Clearance of barbiturates in children is prolonged compared with adults [<a href="#rid42">42</a>]. This difference may be even more exaggerated in neonates and infants, who have relatively higher volumes of distribution and poorly developed cytochrome P450 (CYP) systems [<a href="#rid135">135</a>].</p><p class="headingAnchor" id="H1617569827"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Treatment of a pregnant patient with barbiturate poisoning is the same as for a nonpregnant patient. However, <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> readily crosses the placenta and may be a teratogen; thus, the patient should be referred for appropriate obstetrical evaluation and counseling following the acute intoxication [<a href="#rid136">136</a>]. (See  <a class="medical medical_review" href="/z/d/html/2218.html" rel="external">"Risks associated with epilepsy during pregnancy and the postpartum period", section on 'Phenobarbital'</a>.)</p><p class="headingAnchor" id="H1033694986"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2842428964"><span class="h2">Regional poison centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H420451384"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114014.html" rel="external">"Society guideline links: Treatment of acute poisoning caused by specific agents other than drugs of abuse"</a>.)</p><p class="headingAnchor" id="H3507072754"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacology</strong> – Barbiturates enhance gamma-aminobutyric acid (GABA)-A receptor signaling. Compared with benzodiazepines, barbiturates are more likely to cause respiratory depression in overdose. They are weak acids. The management of long-acting barbiturate (<a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9811" href="/z/d/drug information/9811.html" rel="external">primidone</a>)  (<a class="graphic graphic_table graphicRef143593" href="/z/d/graphic/143593.html" rel="external">table 2</a>) poisoning has unique considerations compared with other barbiturates. (See <a class="local">'Pharmacology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations of overdose</strong> – Barbiturates produce central nervous system depression, respiratory depression, hypotension, and thermoregulatory dysfunction (ie, hypothermia). Severe poisoning can produce coma (occasionally with suppression of brainstem reflexes that mimics brain death), apnea, and cardiovascular collapse. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> – Routine laboratory and diagnostic testing is aimed at excluding other diagnoses and includes serum chemistries, creatinine, complete blood count, serum <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, salicylate, and ethanol concentrations, creatine kinase, and an electrocardiogram. Obtain a serum <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> concentration in a patient with potential phenobarbital exposure. The therapeutic range is 10 to 40 mcg/mL (43 to 172 micromole/L) and concentrations &gt;80 mcg/mL (344 micromole/L) are potentially fatal. Quantitative testing for other barbiturates is not useful in the acute management of the somnolent patient since these assays are not readily available at most clinical laboratories and have long turnaround times. (See <a class="local">'Evaluation and diagnostic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Barbiturate poisoning should be suspected in a patient with depressed mental status and a history of exposure to a barbiturate. The diagnosis of <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> poisoning is confirmed by a supratherapeutic serum phenobarbital concentration (&gt;40 mcg/mL [172 micromole/L]). Other than phenobarbital, barbiturate poisoning is a clinical diagnosis in a patient with depressed mental status and corroborating history (eg, access to barbiturates) or a urine drug screen (if obtained) that detects a barbiturate. In the absence of clear corroborating history, it is a diagnosis of exclusion. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Initial management is with supportive care. A rapid overview table to facilitate emergency management is provided  (<a class="graphic graphic_table graphicRef143592" href="/z/d/graphic/143592.html" rel="external">table 1</a>). We do not administer <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">flumazenil</a> since it may precipitate benzodiazepine withdrawal if the patient has a benzodiazepine coingestion. We do not routinely administer a single dose of activated charcoal in a patient with isolated barbiturate ingestion since intoxication will often improve with supportive care. (See <a class="local">'All patients/barbiturates: supportive care'</a> above and <a class="local">'Gastrointestinal decontamination'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Respiratory depression</strong> – In a somnolent patient with a low respiratory rate, we administer a trial of parenteral or intranasal <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, which would not be expected to reverse the effects of the barbiturate itself. Naloxone may improve mental status or respiration if the patient is also suffering opioid intoxication. Tracheal intubation and mechanical ventilation will most likely be required in a patient with respiratory depression or an inability for airway protection. (See <a class="local">'Respiratory depression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypotension</strong> – Hypotension is treated with a rapid infusion of isotonic crystalloid, followed by vasopressors (eg, norepinephrine, <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">phenylephrine</a>) if needed. (See <a class="local">'Hypotension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">Phenobarbital</a><strong> ingestion with moderate to severe toxicity</strong> – We consider moderate toxicity as depressed mental status that does not improve with verbal stimuli and a phenobarbital concentration &gt;40 mcg/mL [172 micromole/L] and severe toxicity as hypotension requiring the use of vasopressors or cardiovascular collapse. In a patient with moderate to severe toxicity, we suggest multidose activated charcoal (MDAC) and urinary alkalinization in addition to supportive care (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). MDAC increases phenobarbital clearance but should only be performed in a patient with a protected airway, but tracheal intubation should not be performed for the sole purpose of providing MDAC. Urinary alkalinization increases phenobarbital clearance but to a lesser extent compared with MDAC. (See <a class="local">'Patient with phenobarbital poisoning and moderate to severe toxicity'</a> above.) </p><p></p><p class="bulletIndent2">In a patient with severe toxicity or prolonged coma and/or increasing serum <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">phenobarbital</a> concentrations despite MDAC and urinary alkalinization, we recommend hemodialysis in addition to MDAC, urinary alkalinization, and supportive care (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). Intermittent hemodialysis or continuous renal replacement therapy increase phenobarbital clearance but has more potential complications compared with MDAC. (See <a class="local">'Hemodialysis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cozanitis DA. One hundred years of barbiturates and their saint. J R Soc Med 2004; 97:594.</a></li><li><a class="nounderline abstract_t">López-Muñoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 2005; 1:329.</a></li><li><a class="nounderline abstract_t">Herzberg D, Guarino H, Mateu-Gelabert P, Bennett AS. Recurring Epidemics of Pharmaceutical Drug Abuse in America: Time for an All-Drug Strategy. Am J Public Health 2016; 106:408.</a></li><li><a class="nounderline abstract_t">Johns MW. Self-poisoning with barbiturates in England and Wales during 1959-74. Br Med J 1977; 1:1128.</a></li><li><a class="nounderline abstract_t">Whitlock FA. Suicide in Brisbane, 1956 to 1973: the drug-death epidemic. Med J Aust 1975; 1:737.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2021 Annual Report of the National Poison Data System© (NPDS) from America's Poison Centers: 39th Annual Report. Clin Toxicol (Phila) 2022; 60:1381.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report. Clin Toxicol (Phila) 2021; 59:1282.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila) 2019; 57:1220.</a></li><li><a class="nounderline abstract_t">Gummin DD, Mowry JB, Spyker DA, et al. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila) 2018; 56:1213.</a></li><li><a class="nounderline abstract_t">Ibarra F Jr. Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal. Am J Emerg Med 2020; 38:178.</a></li><li><a class="nounderline abstract_t">Sullivan SM, Dewey BN, Jarrell DH, et al. Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the ED. Am J Emerg Med 2019; 37:1313.</a></li><li><a class="nounderline abstract_t">Lebin JA, Mudan A, Murphy CE 4th, et al. Return Encounters in Emergency Department Patients Treated with Phenobarbital Versus Benzodiazepines for Alcohol Withdrawal. J Med Toxicol 2022; 18:4.</a></li><li><a class="nounderline abstract_t">Nelson AC, Kehoe J, Sankoff J, et al. Benzodiazepines vs barbiturates for alcohol withdrawal: Analysis of 3 different treatment protocols. Am J Emerg Med 2019; 37:733.</a></li><li><a class="nounderline abstract_t">Darke S, Chrzanowska A, Campbell G, et al. Barbiturate-related hospitalisations, drug treatment episodes, and deaths in Australia, 2000-2018. Med J Aust 2022; 216:194.</a></li><li><a class="nounderline abstract_t">van den Hondel KE, Punt P, Dorn T, et al. The rise of suicides using a deadly dose of barbiturates in Amsterdam and Rotterdam, the Netherlands, between 2006 and 2017. J Forensic Leg Med 2020; 70:101916.</a></li><li><a class="nounderline abstract_t">Campbell G, Darke S, Zahra E, et al. Trends and characteristics in barbiturate deaths Australia 2000-2019: a national retrospective study. Clin Toxicol (Phila) 2021; 59:224.</a></li><li><a class="nounderline abstract_t">Campbell G, Darke S, Hall W, Lappin J. Increased barbiturate deaths: an unintended consequence of increased publicity for methods of do-it-yourself euthanasia? Addiction 2021; 116:3273.</a></li><li class="breakAll">Curry SC, O'Connor AD, Graeme KA, Min Kang AA. Neurotransmitters and neuromodulators. In: Goldfrank's Toxicologic Emergencies, 11e, Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS (Eds), McGraw Hill, 2019.</li><li><a class="nounderline abstract_t">Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 1995; 47:181.</a></li><li><a class="nounderline abstract_t">Rho JM, Donevan SD, Rogawski MA. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. J Physiol 1996; 497 ( Pt 2):509.</a></li><li><a class="nounderline abstract_t">Thompson SA, Whiting PJ, Wafford KA. Barbiturate interactions at the human GABAA receptor: dependence on receptor subunit combination. Br J Pharmacol 1996; 117:521.</a></li><li><a class="nounderline abstract_t">Olney JW, Labruyere J, Wang G, et al. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991; 254:1515.</a></li><li><a class="nounderline abstract_t">Daniell LC. Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles. Pharmacology 1994; 49:296.</a></li><li><a class="nounderline abstract_t">Hendey GW, Dery RA, Barnes RL, et al. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. Am J Emerg Med 2011; 29:382.</a></li><li><a class="nounderline abstract_t">Rosenson J, Clements C, Simon B, et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. J Emerg Med 2013; 44:592.</a></li><li><a class="nounderline abstract_t">Shah P, Stegner-Smith KL, Rachid M, et al. Front-Loaded Versus Low-Intermittent Phenobarbital Dosing for Benzodiazepine-Resistant Severe Alcohol Withdrawal Syndrome. J Med Toxicol 2022; 18:198.</a></li><li><a class="nounderline abstract_t">Ondo WG. Current and Emerging Treatments of Essential Tremor. Neurol Clin 2020; 38:309.</a></li><li><a class="nounderline abstract_t">Hopfner F, Deuschl G. Managing Essential Tremor. Neurotherapeutics 2020; 17:1603.</a></li><li><a class="nounderline abstract_t">Christidis D, Kalogerakis D, Chan TY, et al. Is primidone the drug of choice for epileptic patients with QT-prolongation? A comprehensive analysis of literature. Seizure 2006; 15:64.</a></li><li><a class="nounderline abstract_t">DeSilvey DL, Moss AJ. Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression. Ann Intern Med 1980; 93:53.</a></li><li><a class="nounderline abstract_t">Avramov MN, Husain MM, White PF. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy. Anesth Analg 1995; 81:596.</a></li><li><a class="nounderline abstract_t">Wyler AR, Richey ET, Atkinson RA, Hermann BP. Methohexital activation of epileptogenic foci during acute electrocorticography. Epilepsia 1987; 28:490.</a></li><li><a class="nounderline abstract_t">Willeford A, Trumm N, Bisanz B, et al. Methohexital-Induced Seizure in a Patient Undergoing Conscious Sedation. J Emerg Med 2020; 59:224.</a></li><li><a class="nounderline abstract_t">Eisenberg HM, Frankowski RF, Contant CF, et al. High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury. J Neurosurg 1988; 69:15.</a></li><li><a class="nounderline abstract_t">Marshall GT, James RF, Landman MP, et al. Pentobarbital coma for refractory intra-cranial hypertension after severe traumatic brain injury: mortality predictions and one-year outcomes in 55 patients. J Trauma 2010; 69:275.</a></li><li><a class="nounderline abstract_t">Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49:1239.</a></li><li><a class="nounderline abstract_t">Nelson E, Powell JR, Conrad K, et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol 1982; 22:141.</a></li><li><a class="nounderline abstract_t">Pitlick W, Painter M, Pippenger C. Phenobarbital pharmacokinetics in neonates. Clin Pharmacol Ther 1978; 23:346.</a></li><li><a class="nounderline abstract_t">Turcant A, Delhumeau A, Premel-Cabic A, et al. Thiopental pharmacokinetics under conditions of long-term infusion. Anesthesiology 1985; 63:50.</a></li><li><a class="nounderline abstract_t">Patsalos PN, Zugman M, Lake C, et al. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations. Epilepsia 2017; 58:1234.</a></li><li><a class="nounderline abstract_t">Patsalos PN, Spencer EP, Berry DJ. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther Drug Monit 2018; 40:526.</a></li><li><a class="nounderline abstract_t">Klaassen CD. Biliary excretion of barbiturates. Br J Pharmacol 1971; 43:161.</a></li><li><a class="nounderline abstract_t">Waxman DJ, Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 1992; 281 ( Pt 3):577.</a></li><li><a class="nounderline abstract_t">Hole K, Wollmann BM, Nguyen C, et al. Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker. Ther Drug Monit 2018; 40:463.</a></li><li><a class="nounderline abstract_t">Russo H, Bressolle F. Pharmacodynamics and pharmacokinetics of thiopental. Clin Pharmacokinet 1998; 35:95.</a></li><li><a class="nounderline abstract_t">Senderovich H, Waicus S, Mokenela K. Evading Seizures: Phenobarbital Reintroduced as a Multifunctional Approach to End-of-Life Care. Case Rep Oncol 2022; 15:218.</a></li><li><a class="nounderline abstract_t">Mohammed Ebid AH, Abdel-Rahman HM. Pharmacokinetics of phenobarbital during certain enhanced elimination modalities to evaluate their clinical efficacy in management of drug overdose. Ther Drug Monit 2001; 23:209.</a></li><li><a class="nounderline abstract_t">Frenia ML, Schauben JL, Wears RL, et al. Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination. J Toxicol Clin Toxicol 1996; 34:169.</a></li><li><a class="nounderline abstract_t">Proudfoot AT, Krenzelok EP, Vale JA. Position Paper on urine alkalinization. J Toxicol Clin Toxicol 2004; 42:1.</a></li><li><a class="nounderline abstract_t">Grattan-Smith PJ, Butt W. Suppression of brainstem reflexes in barbiturate coma. Arch Dis Child 1993; 69:151.</a></li><li><a class="nounderline abstract_t">Murphy L, Wolfer H, Hendrickson RG. Toxicologic Confounders of Brain Death Determination: A Narrative Review. Neurocrit Care 2021; 34:1072.</a></li><li><a class="nounderline abstract_t">Kaufman HH, Geisler FH, Kopitnik T, et al. Detection of brain death in barbiturate coma: the dilemma of an intracranial pulse. Neurosurgery 1989; 25:275.</a></li><li><a class="nounderline abstract_t">Druda DF, Gone S, Graudins A. Deliberate Self-poisoning with a Lethal Dose of Pentobarbital with Confirmatory Serum Drug Concentrations: Survival After Cardiac Arrest with Supportive Care. J Med Toxicol 2019; 15:45.</a></li><li><a class="nounderline abstract_t">Cohn MA. Hypnotics and the control of breathing: a review. Br J Clin Pharmacol 1983; 16 Suppl 2:245S.</a></li><li><a class="nounderline abstract_t">Gautier H, Offenstadt G, Kaczmarek R, et al. Pattern of respiration in patients recovering from barbiturate overdose. Br J Anaesth 1982; 54:1041.</a></li><li><a class="nounderline abstract_t">SWERDLOW M. Respiratory effects of the thiobarbiturates. Br J Anaesth 1958; 30:2.</a></li><li><a class="nounderline abstract_t">Saraswat V. Effects of anaesthesia techniques and drugs on pulmonary function. Indian J Anaesth 2015; 59:557.</a></li><li><a class="nounderline abstract_t">Löscher W, Rogawski MA. How theories evolved concerning the mechanism of action of barbiturates. Epilepsia 2012; 53 Suppl 8:12.</a></li><li><a class="nounderline abstract_t">Webster LR, Karan S. The Physiology and Maintenance of Respiration: A Narrative Review. Pain Ther 2020; 9:467.</a></li><li><a class="nounderline abstract_t">Traeger SM, Henning RJ, Dobkin W, et al. Hemodynamic effects of pentobarbital therapy for intracranial hypertension. Crit Care Med 1983; 11:697.</a></li><li><a class="nounderline abstract_t">Goodman JM, Bischel MD, Wagers PW, Barbour BH. Barbiturate intoxication. Morbidity and mortality. West J Med 1976; 124:179.</a></li><li><a class="nounderline abstract_t">SHUBIN H, WEIL MH. THE MECHANISM OF SHOCK FOLLOWING SUICIDAL DOSES OF BARBITURATES, NARCOTICS AND TRANQUILIZER DRUGS, WITH OBSERVATIONS ON THE EFFECTS OF TREATMENT. Am J Med 1965; 38:853.</a></li><li><a class="nounderline abstract_t">Shubin H, Weil MH. Shock associated with barbiturate intoxication. JAMA 1971; 215:263.</a></li><li><a class="nounderline abstract_t">Grounds RM, Twigley AJ, Carli F, et al. The haemodynamic effects of intravenous induction. Comparison of the effects of thiopentone and propofol. Anaesthesia 1985; 40:735.</a></li><li><a class="nounderline abstract_t">Mulier JP, Wouters PF, Van Aken H, et al. Cardiodynamic effects of propofol in comparison with thiopental: assessment with a transesophageal echocardiographic approach. Anesth Analg 1991; 72:28.</a></li><li><a class="nounderline abstract_t">ETSTEN B, LI TH. Hemodynamic changes during thiopental anesthesia in humans: cardiac output, stroke volume, total peripheral resistance, and intrathoracic blood volume. J Clin Invest 1955; 34:500.</a></li><li><a class="nounderline abstract_t">Price ML, Millar B, Grounds M, Cashman J. Changes in cardiac index and estimated systemic vascular resistance during induction of anaesthesia with thiopentone, methohexitone, propofol and etomidate. Br J Anaesth 1992; 69:172.</a></li><li><a class="nounderline abstract_t">Roesch C, Haselby KA, Paradise RR, et al. Comparison of cardiovascular effects of thiopental and pentobarbital at equivalent levels of CNS depression. Anesth Analg 1983; 62:749.</a></li><li><a class="nounderline abstract_t">Reiz S, Bålfors E, Friedman A, et al. Effects of thiopentone on cardiac performance, coronary hemodynamics and myocardial oxygen consumption in chronic ischemic heart disease. Acta Anaesthesiol Scand 1981; 25:103.</a></li><li><a class="nounderline abstract_t">Dominguez de villota E, Shubin H, Weil MH. Oxygen transport, consumption and utilization during barbiturate intoxication. Intensive Care Med 1982; 8:275.</a></li><li><a class="nounderline abstract_t">Liu S, Chen JF. Strategies for therapeutic hypometabothermia. J Exp Stroke Transl Med 2012; 5:31.</a></li><li><a class="nounderline abstract_t">Lash RF, Burdette JA, Ozdil T. Accidental profound hypothermia and barbiturate intoxication. A report of rapid "core" rewarming by peritoneal dialysis. JAMA 1967; 201:269.</a></li><li><a class="nounderline abstract_t">Linton AL, Ledingham IM. Severe hypothermia with barbiturate intoxication. Lancet 1966; 1:24.</a></li><li><a class="nounderline abstract_t">Amitai Y, Degani Y. Treatment of phenobarbital poisoning with multiple dose activated charcoal in an infant. J Emerg Med 1990; 8:449.</a></li><li><a class="nounderline abstract_t">Koizumi Y, Higashitani M, Fukui S, et al. A Case of Barbiturate Poisoning From Pentobarbital in a Young Japanese Patient. Cureus 2023; 15:e36498.</a></li><li><a class="nounderline abstract_t">de Villota ED, Mosquera JM, Shubin H, Weil MH. Abnormal temperature control after intoxication with short-acting barbiturates. Crit Care Med 1981; 9:662.</a></li><li><a class="nounderline abstract_t">BEVERIDGE GW, LAWSON AA. OCCURRENCE OF BULLOUS LESIONS IN ACUTE BARBITURATE INTOXICATION. Br Med J 1965; 1:835.</a></li><li><a class="nounderline abstract_t">Borda IT. Barbiturate coma bullae. JAMA 1970; 214:1564.</a></li><li><a class="nounderline abstract_t">Rocha J, Pereira T, Ventura F, et al. Coma Blisters. Case Rep Dermatol 2009; 1:66.</a></li><li><a class="nounderline abstract_t">Torres-Navarro I, Pujol-Marco C, Roca-Ginés J, Botella-Estrada R. Coma blisters. A key to neurological diagnosis. Neurologia (Engl Ed) 2020; 35:512.</a></li><li><a class="nounderline abstract_t">Bosco L, Schena D, Colato C, et al. Coma blisters in children: case report and review of the literature. J Child Neurol 2013; 28:1677.</a></li><li><a class="nounderline abstract_t">Keng M, Lagos M, Liepman MR, Trever K. Phenobarbital-induced bullous lesions in a non-comatose patient. Psychiatry (Edgmont) 2006; 3:65.</a></li><li><a class="nounderline abstract_t">Ferreli C, Sulica VI, Aste N, et al. Drug-induced sweat gland necrosis in a non-comatose patient: a case presentation. J Eur Acad Dermatol Venereol 2003; 17:443.</a></li><li><a class="nounderline abstract_t">Waring WS, Sandilands EA. Coma blisters. Clin Toxicol (Phila) 2007; 45:808.</a></li><li><a class="nounderline abstract_t">Varma AJ, Fisher BK, Sarin MK. Diazepam-induced coma with bullae and eccrine sweat gland necrosis. Arch Intern Med 1977; 137:1207.</a></li><li><a class="nounderline abstract_t">Moshkowitz M, Pines A, Finkelstein A, et al. Skin blisters as a manifestation of oxazepam toxicity. J Toxicol Clin Toxicol 1990; 28:383.</a></li><li><a class="nounderline abstract_t">Wiegand TJ, Gorodetsky RM, Peredy TR. Coma blisters in the setting of quetiapine overdose: Case report and review of literature. Asia Pac J Med Toxicol 2013; 2:153.</a></li><li><a class="nounderline abstract_t">You MY, Yun SK, Ihm W. Bullae and sweat gland necrosis after an alcoholic deep slumber. Cutis 2002; 69:265.</a></li><li><a class="nounderline abstract_t">Dunn C, Held JL, Spitz J, et al. Coma blisters: report and review. Cutis 1990; 45:423.</a></li><li><a class="nounderline abstract_t">Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009; 145:67.</a></li><li><a class="nounderline abstract_t">Witcher RH, Ramirez MM. Successful Phenobarbital Desensitization After DRESS Reaction in the Management of Refractory Status Epilepticus. J Pharm Pract 2019; 32:228.</a></li><li><a class="nounderline abstract_t">Baruzzi A, Contin M, Barbara G, et al. Drug rash with eosinophilia and systemic symptoms secondary to phenobarbitone. Clin Neuropharmacol 2003; 26:177.</a></li><li><a class="nounderline abstract_t">Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124:588.</a></li><li><a class="nounderline abstract_t">Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 353:2190.</a></li><li class="breakAll">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Barbiturates. [Updated 2021 Oct 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548260/.</li><li><a class="nounderline abstract_t">Bledsoe KA, Kramer AH. Propylene glycol toxicity complicating use of barbiturate coma. Neurocrit Care 2008; 9:122.</a></li><li><a class="nounderline abstract_t">Smedley LW, Rios D, Barthol CA, Garvin RE. Iatrogenic Propylene Glycol Intoxication Due to High-Dose Pentobarbital for Refractory Intracranial Hypertension: A Case Report. J Pharm Pract 2020; 33:895.</a></li><li><a class="nounderline abstract_t">Miller MA, Forni A, Yogaratnam D. Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital. Ann Pharmacother 2008; 42:1502.</a></li><li><a class="nounderline abstract_t">Schalén W, Messeter K, Nordström CH. Complications and side effects during thiopentone therapy in patients with severe head injuries. Acta Anaesthesiol Scand 1992; 36:369.</a></li><li><a class="nounderline abstract_t">Jung JY, Lee C, Ro H, et al. Sequential occurrence of life-threatening hypokalemia and rebound hyperkalemia associated with barbiturate coma therapy. Clin Nephrol 2009; 71:333.</a></li><li><a class="nounderline abstract_t">Cairns CJ, Thomas B, Fletcher S, et al. Life-threatening hyperkalaemia following therapeutic barbiturate coma. Intensive Care Med 2002; 28:1357.</a></li><li><a class="nounderline abstract_t">Neil MJ, Dale MC. Hypokalaemia with severe rebound hyperkalaemia after therapeutic barbiturate coma. Anesth Analg 2009; 108:1867.</a></li><li><a class="nounderline abstract_t">Ng SY, Chin KJ, Kwek TK. Dyskalaemia associated with thiopentone barbiturate coma for refractory intracranial hypertension: a case series. Intensive Care Med 2011; 37:1285.</a></li><li><a class="nounderline abstract_t">Kwon HM, Baek JW, Lee SP, Cho JI. A Fatal Adverse Effect of Barbiturate Coma Therapy: Dyskalemia. Korean J Neurotrauma 2016; 12:156.</a></li><li><a class="nounderline abstract_t">Awad M, Bonitz J, Pratt A. Pentobarbital Induced Hypokalemia: A Worrying Sequela. Int J Surg Case Rep 2020; 71:323.</a></li><li><a class="nounderline abstract_t">Smith K, Crall W, Gagnon D, et al. Evaluation of serum potassium during pentobarbital administration in critically ill patients. Crit Care Med 2019; 47:401.</a></li><li><a class="nounderline abstract_t">Friederich P, Urban BW. Interaction of intravenous anesthetics with human neuronal potassium currents in relation to clinical concentrations. Anesthesiology 1999; 91:1853.</a></li><li><a class="nounderline abstract_t">Lehmann DF. Primidone crystalluria following overdose. A report of a case and an analysis of the literature. Med Toxicol Adverse Drug Exp 1987; 2:383.</a></li><li><a class="nounderline abstract_t">National Poisons Information Service, Association of Clinical Biochemists. Laboratory analyses for poisoned patients: joint position paper. Ann Clin Biochem 2002; 39:328.</a></li><li><a class="nounderline abstract_t">Mactier R, Laliberté M, Mardini J, et al. Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup. Am J Kidney Dis 2014; 64:347.</a></li><li><a class="nounderline abstract_t">Hoyland K, Hoy M, Austin R, Wildman M. Successful use of haemodialysis to treat phenobarbital overdose. BMJ Case Rep 2013; 2013.</a></li><li><a class="nounderline abstract_t">McCarron MM, Schulze BW, Walberg CB, et al. Short-acting barbiturate overdosage. Correlation of intoxication score with serum barbiturate concentration. JAMA 1982; 248:55.</a></li><li><a class="nounderline abstract_t">Neavyn MJ, Stolbach A, Greer DM, et al. ACMT Position Statement: Determining Brain Death in Adults After Drug Overdose. J Med Toxicol 2017; 13:271.</a></li><li><a class="nounderline abstract_t">Krasowski MD, Pizon AF, Siam MG, et al. Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med 2009; 9:5.</a></li><li><a class="nounderline abstract_t">Christian MR, Lowry JA, Algren DA, et al. Do rapid comprehensive urine drug screens change clinical management in children? Clin Toxicol (Phila) 2017; 55:977.</a></li><li><a class="nounderline abstract_t">Saitman A, Park HD, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol 2014; 38:387.</a></li><li><a class="nounderline abstract_t">Rollins DE, Jennison TA, Jones G. Investigation of interference by nonsteroidal anti-inflammatory drugs in urine tests for abused drugs. Clin Chem 1990; 36:602.</a></li><li><a class="nounderline abstract_t">San-José P, Cano-Corres R, Aguadero V, et al. Interference between ethosuximide and barbiturates in an immunochromatographic method. Clin Chem Lab Med 2018; 56:e50.</a></li><li><a class="nounderline abstract_t">Palmer BF. Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose. Am J Kidney Dis 2000; 36:640.</a></li><li><a class="nounderline abstract_t">Pond SM, Olson KR, Osterloh JD, Tong TG. Randomized study of the treatment of phenobarbital overdose with repeated doses of activated charcoal. JAMA 1984; 251:3104.</a></li><li><a class="nounderline abstract_t">Boldy DA, Vale JA, Prescott LF. Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal. Q J Med 1986; 61:997.</a></li><li><a class="nounderline abstract_t">Arimori K, Nakano M. Accelerated clearance of intravenously administered theophylline and phenobarbital by oral doses of activated charcoal in rats. A possibility of the intestinal dialysis. J Pharmacobiodyn 1986; 9:437.</a></li><li><a class="nounderline abstract_t">Neuvonen PJ, Elonen E. Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol 1980; 17:51.</a></li><li><a class="nounderline abstract_t">Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1999; 37:731.</a></li><li><a class="nounderline abstract_t">Mawer GE, Lee HA. Value of forced diuresis in acute barbiturate poisoning. Br Med J 1968; 2:790.</a></li><li><a class="nounderline abstract_t">Linton AL, Luke RG, Briggs JD. Methods of forced diuresis and its application in barbiturate poisoning. Lancet 1967; 2:377.</a></li><li><a class="nounderline abstract_t">MYSCHETZKY A, LASSEN NA. UREA-INDUCED, OSMOTIC DIURESIS AND ALKALIZATION OF URINE IN ACUTE BARBITURATE INTOXICATION. JAMA 1963; 185:936.</a></li><li><a class="nounderline abstract_t">Ruhe M, Grautoff S, Kähler J, Pohle T. [Suicide attempt by means of phenobarbital overdose. Effective treatment with continuous veno-venous hemodialysis]. Med Klin Intensivmed Notfmed 2016; 111:141.</a></li><li><a class="nounderline abstract_t">Kohara S, Kamijo Y, Seki S, Hasegawa E. Poisoning by abnormally high blood phenobarbital concentration treated with extracorporeal therapy. Am J Emerg Med 2023; 72:221.e5.</a></li><li><a class="nounderline abstract_t">Rosenborg S, Saraste L, Wide K. High phenobarbital clearance during continuous renal replacement therapy: a case report and pharmacokinetic analysis. Medicine (Baltimore) 2014; 93:e46.</a></li><li><a class="nounderline abstract_t">Thuan LQ, Ngoc ND, Due P. Effectiveness of Continuous Veno-Venous Hemofiltration and Intermittent Hemodialysis in the Treatment of Severe Acute Phenobarbital Poisoning. Asia Pacific Journal of Medical Toxicology 2013; 2:10.</a></li><li><a class="nounderline abstract_t">Agarwal SK, Tiwari SC, Dash SC. Spectrum of poisoning requiring haemodialysis in a tertiary care hospital in India. Int J Artif Organs 1993; 16:20.</a></li><li><a class="nounderline abstract_t">Botti P, Garcia S, Dannaoui B, et al. Hemodialysis vs. Forced Alkaline Diuresis in Acute Barbiturate Poisoning [abstract]. Clin Toxicol (Phila) 2004; 42:518.</a></li><li><a class="nounderline abstract_t">Fernandez E, Perez R, Hernandez A, et al. Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults. Pharmaceutics 2011; 3:53.</a></li><li><a class="nounderline abstract_t">Czeizel AE, Dudás I, Bánhidy F. Interpretation of controversial teratogenic findings of drugs such as phenobarbital. ISRN Obstet Gynecol 2011; 2011:719675.</a></li></ol></div><div id="topicVersionRevision">Topic 13844 Version 3.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15574863" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : One hundred years of barbiturates and their saint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18568113" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The history of barbiturates a century after their clinical introduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26794163" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Recurring Epidemics of Pharmaceutical Drug Abuse in America: Time for an All-Drug Strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/861497" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Self-poisoning with barbiturates in England and Wales during 1959-74.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/239307" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Suicide in Brisbane, 1956 to 1973: the drug-death epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36602072" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2021 Annual Report of the National Poison Data System©(NPDS) from America's Poison Centers: 39th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34890263" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2020 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 38th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31752545" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30576252" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30744913" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Single dose phenobarbital in addition to symptom-triggered lorazepam in alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30414743" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of phenobarbital-adjunct versus benzodiazepine-only approach for alcohol withdrawal syndrome in the ED.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34697777" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Return Encounters in Emergency Department Patients Treated with Phenobarbital Versus Benzodiazepines for Alcohol Withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30685075" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Benzodiazepines vs barbiturates for alcohol withdrawal: Analysis of 3 different treatment protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34658038" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Barbiturate-related hospitalisations, drug treatment episodes, and deaths in Australia, 2000-2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32090971" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The rise of suicides using a deadly dose of barbiturates in Amsterdam and Rotterdam, the Netherlands, between 2006 and 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32633579" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Trends and characteristics in barbiturate deaths Australia 2000-2019: a national retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34382271" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increased barbiturate deaths: an unintended consequence of increased publicity for methods of do-it-yourself euthanasia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34382271" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Increased barbiturate deaths: an unintended consequence of increased publicity for methods of do-it-yourself euthanasia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7568326" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8961191" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8821543" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Barbiturate interactions at the human GABAA receptor: dependence on receptor subunit combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1835799" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : NMDA antagonist neurotoxicity: mechanism and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862741" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effect of anesthetic and convulsant barbiturates on N-methyl-D-aspartate receptor-mediated calcium flux in brain membrane vesicles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20825805" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22999778" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35668289" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Front-Loaded Versus Low-Intermittent Phenobarbital Dosing for Benzodiazepine-Resistant Severe Alcohol Withdrawal Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32279712" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Current and Emerging Treatments of Essential Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32915385" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Managing Essential Tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16309926" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Is primidone the drug of choice for epileptic patients with QT-prolongation? A comprehensive analysis of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7396315" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7653829" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3653051" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Methohexital activation of epileptogenic foci during acute electrocorticography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32565170" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Methohexital-Induced Seizure in a Patient Undergoing Conscious Sedation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3288723" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : High-dose barbiturate control of elevated intracranial pressure in patients with severe head injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20699736" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pentobarbital coma for refractory intra-cranial hypertension after severe traumatic brain injury: mortality predictions and one-year outcomes in 55 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18397299" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7068937" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Phenobarbital pharmacokinetics and bioavailability in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/627141" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Phenobarbital pharmacokinetics in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4014770" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Thiopental pharmacokinetics under conditions of long-term infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28542801" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29957667" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5136456" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Biliary excretion of barbiturates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1536639" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Phenobarbital induction of cytochrome P-450 gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29649093" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of CYP3A4-Inducing Capacity of Enzyme-Inducing Antiepileptic Drugs Using 4β-Hydroxycholesterol as Biomarker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9739479" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pharmacodynamics and pharmacokinetics of thiopental.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35431869" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Evading Seizures: Phenobarbital Reintroduced as a Multifunctional Approach to End-of-Life Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11360027" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pharmacokinetics of phenobarbital during certain enhanced elimination modalities to evaluate their clinical efficacy in management of drug overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8618250" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Multiple-dose activated charcoal compared to urinary alkalinization for the enhancement of phenobarbital elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15083932" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Position Paper on urine alkalinization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8024301" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Suppression of brainstem reflexes in barbiturate coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33000377" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Toxicologic Confounders of Brain Death Determination: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2770991" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Detection of brain death in barbiturate coma: the dilemma of an intracranial pulse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30073621" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Deliberate Self-poisoning with a Lethal Dose of Pentobarbital with Confirmatory Serum Drug Concentrations: Survival After Cardiac Arrest with Supportive Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6140945" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hypnotics and the control of breathing: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7126398" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pattern of respiration in patients recovering from barbiturate overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13510499" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Respiratory effects of the thiobarbiturates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26556914" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effects of anaesthesia techniques and drugs on pulmonary function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23205959" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : How theories evolved concerning the mechanism of action of barbiturates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33021707" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The Physiology and Maintenance of Respiration: A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6884049" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Hemodynamic effects of pentobarbital therapy for intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1258466" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Barbiturate intoxication. Morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14310001" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : THE MECHANISM OF SHOCK FOLLOWING SUICIDAL DOSES OF BARBITURATES, NARCOTICS AND TRANQUILIZER DRUGS, WITH OBSERVATIONS ON THE EFFECTS OF TREATMENT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5107363" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Shock associated with barbiturate intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3876040" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The haemodynamic effects of intravenous induction. Comparison of the effects of thiopentone and propofol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984373" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cardiodynamic effects of propofol in comparison with thiopental: assessment with a transesophageal echocardiographic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14354021" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hemodynamic changes during thiopental anesthesia in humans: cardiac output, stroke volume, total peripheral resistance, and intrathoracic blood volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1389822" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Changes in cardiac index and estimated systemic vascular resistance during induction of anaesthesia with thiopentone, methohexitone, propofol and etomidate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6869862" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Comparison of cardiovascular effects of thiopental and pentobarbital at equivalent levels of CNS depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7324816" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Effects of thiopentone on cardiac performance, coronary hemodynamics and myocardial oxygen consumption in chronic ischemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7175011" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Oxygen transport, consumption and utilization during barbiturate intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24179563" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Strategies for therapeutic hypometabothermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5630617" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Accidental profound hypothermia and barbiturate intoxication. A report of rapid "core" rewarming by peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4159158" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Severe hypothermia with barbiturate intoxication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2212564" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Treatment of phenobarbital poisoning with multiple dose activated charcoal in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37090268" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A Case of Barbiturate Poisoning From Pentobarbital in a Young Japanese Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7273815" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Abnormal temperature control after intoxication with short-acting barbiturates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14258848" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : OCCURRENCE OF BULLOUS LESIONS IN ACUTE BARBITURATE INTOXICATION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5536359" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Barbiturate coma bullae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20652118" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Coma Blisters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30857784" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Coma blisters. A key to neurological diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23155203" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Coma blisters in children: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20877558" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Phenobarbital-induced bullous lesions in a non-comatose patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12834457" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Drug-induced sweat gland necrosis in a non-comatose patient: a case presentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17952753" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Coma blisters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/332103" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Diazepam-induced coma with bullae and eccrine sweat gland necrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2231838" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Skin blisters as a manifestation of oxazepam toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Coma blisters in the setting of quetiapine overdose: Case report and review of literature</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12080944" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Bullae and sweat gland necrosis after an alcoholic deep slumber.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2350978" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Coma blisters: report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153346" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29390946" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Successful Phenobarbital Desensitization After DRESS Reaction in the Management of Refractory Status Epilepticus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12897635" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Drug rash with eosinophilia and systemic symptoms secondary to phenobarbitone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21592453" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The DRESS syndrome: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392983" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10392983" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18270846" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Propylene glycol toxicity complicating use of barbiturate coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31238770" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Iatrogenic Propylene Glycol Intoxication Due to High-Dose Pentobarbital for Refractory Intracranial Hypertension: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18698010" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1595344" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Complications and side effects during thiopentone therapy in patients with severe head injuries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281748" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Sequential occurrence of life-threatening hypokalemia and rebound hyperkalemia associated with barbiturate coma therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209290" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Life-threatening hyperkalaemia following therapeutic barbiturate coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448214" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Hypokalaemia with severe rebound hyperkalaemia after therapeutic barbiturate coma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21567112" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Dyskalaemia associated with thiopentone barbiturate coma for refractory intracranial hypertension: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27857927" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A Fatal Adverse Effect of Barbiturate Coma Therapy: Dyskalemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32492644" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Pentobarbital Induced Hypokalemia: A Worrying Sequela.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Evaluation of serum potassium during pentobarbital administration in critically ill patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10598630" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Interaction of intravenous anesthetics with human neuronal potassium currents in relation to clinical concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3312932" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Primidone crystalluria following overdose. A report of a case and an analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12117436" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Laboratory analyses for poisoned patients: joint position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24998037" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24265338" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Successful use of haemodialysis to treat phenobarbital overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7087092" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Short-acting barbiturate overdosage. Correlation of intoxication score with serum barbiturate concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28255927" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : ACMT Position Statement: Determining Brain Death in Adults After Drug Overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19400959" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28594290" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Do rapid comprehensive urine drug screens change clinical management in children?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24986836" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : False-positive interferences of common urine drug screen immunoassays: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2323039" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Investigation of interference by nonsteroidal anti-inflammatory drugs in urine tests for abused drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28763298" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Interference between ethosuximide and barbiturates in an immunochromatographic method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10977799" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Effectiveness of hemodialysis in the extracorporeal therapy of phenobarbital overdose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6726981" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Randomized study of the treatment of phenobarbital overdose with repeated doses of activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3659250" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Treatment of phenobarbitone poisoning with repeated oral administration of activated charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3761133" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Accelerated clearance of intravenously administered theophylline and phenobarbital by oral doses of activated charcoal in rats. A possibility of the intestinal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7371700" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10584586" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5656296" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Value of forced diuresis in acute barbiturate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4166328" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Methods of forced diuresis and its application in barbiturate poisoning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14044226" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : UREA-INDUCED, OSMOTIC DIURESIS AND ALKALIZATION OF URINE IN ACUTE BARBITURATE INTOXICATION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070921" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : [Suicide attempt by means of phenobarbital overdose. Effective treatment with continuous veno-venous hemodialysis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37635049" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Poisoning by abnormally high blood phenobarbital concentration treated with extracorporeal therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25101986" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : High phenobarbital clearance during continuous renal replacement therapy: a case report and pharmacokinetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Effectiveness of Continuous Veno-Venous Hemofiltration and Intermittent Hemodialysis in the Treatment of Severe Acute Phenobarbital Poisoning</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8458667" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Spectrum of poisoning requiring haemodialysis in a tertiary care hospital in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Hemodialysis vs. Forced Alkaline Diuresis in Acute Barbiturate Poisoning [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24310425" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21904684" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Interpretation of controversial teratogenic findings of drugs such as phenobarbital.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
